Trial of ABL103 with pembrolizumab and chemo for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called ABL103 combined with pembrolizumab (immunotherapy) and with or without a chemotherapy drug called taxane. It is for people with advanced or metastatic solid tumors that have stopped responding to standard treatments or cannot tolerate them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a solid tumor that has spread to other parts of the body or cannot be removed by surgery.
- Standard treatments no longer work for you, or you are unable to tolerate them.
- You are reasonably active and able to care for yourself (ECOG status 0 or 1).
- You have recovered from side effects of previous treatments, except for hair loss or stable nerve pain.
- You have acceptable blood counts, liver, kidney, and thyroid function.
- If you can become pregnant or father a child, you must agree to use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
This trial tests a new drug called ABL103 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
This trial tests ABX-001, a new immunotherapy, alone or with pembrolizumab, for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. It may help if your tumor has become resistant to previous immunotherapies.
This early-stage trial tests a new investigational drug (ADG126) combined with pembrolizumab in people with advanced or metastatic solid tumors. It aims to find a safe dose and see whether the combination can shrink tumors.
This study tests a new drug called PLN-101095 in people with advanced solid tumors whose cancer has stopped responding to a common immunotherapy. The goal is to see if combining this new drug with pembrolizumab can help control the cancer again.
This Phase 1 trial tests the safety and side effects of ABL503 and finds the best dose to study next. It is for people with advanced cancer that is growing despite prior treatment options.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.